153 related articles for article (PubMed ID: 30375995)
1. Meta-mining of copy number profiles of high-risk neuroblastoma tumors.
Depuydt P; Koster J; Boeva V; Hocking TD; Speleman F; Schleiermacher G; De Preter K
Sci Data; 2018 Oct; 5():180240. PubMed ID: 30375995
[TBL] [Abstract][Full Text] [Related]
2. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
[TBL] [Abstract][Full Text] [Related]
3. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Depuydt P; Boeva V; Hocking TD; Cannoodt R; Ambros IM; Ambros PF; Asgharzadeh S; Attiyeh EF; Combaret V; Defferrari R; Fischer M; Hero B; Hogarty MD; Irwin MS; Koster J; Kreissman S; Ladenstein R; Lapouble E; Laureys G; London WB; Mazzocco K; Nakagawara A; Noguera R; Ohira M; Park JR; Pötschger U; Theissen J; Tonini GP; Valteau-Couanet D; Varesio L; Versteeg R; Speleman F; Maris JM; Schleiermacher G; De Preter K
J Natl Cancer Inst; 2018 Oct; 110(10):1084-1093. PubMed ID: 29514301
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
5. Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.
Van Roy N; Van Der Linden M; Menten B; Dheedene A; Vandeputte C; Van Dorpe J; Laureys G; Renard M; Sante T; Lammens T; De Wilde B; Speleman F; De Preter K
Clin Cancer Res; 2017 Oct; 23(20):6305-6314. PubMed ID: 28710315
[No Abstract] [Full Text] [Related]
6. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
[TBL] [Abstract][Full Text] [Related]
7. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases.
Cobrinik D; Ostrovnaya I; Hassimi M; Tickoo SK; Cheung IY; Cheung NK
Genes Chromosomes Cancer; 2013 Dec; 52(12):1150-66. PubMed ID: 24123354
[TBL] [Abstract][Full Text] [Related]
8. Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state.
Lundberg G; Jin Y; Sehic D; Øra I; Versteeg R; Gisselsson D
PLoS One; 2013; 8(3):e59268. PubMed ID: 23555645
[TBL] [Abstract][Full Text] [Related]
9. Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.
Carlsson E; Krohn K; Ovaska K; Lindberg P; Häyry V; Maliniemi P; Lintulahti A; Korja M; Kivisaari R; Hussein S; Sarna S; Niiranen K; Hautaniemi S; Haapasalo H; Ranki A
Genes Chromosomes Cancer; 2013 Feb; 52(2):191-201. PubMed ID: 23097141
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.
George RE; Attiyeh EF; Li S; Moreau LA; Neuberg D; Li C; Fox EA; Meyerson M; Diller L; Fortina P; Look AT; Maris JM
PLoS One; 2007 Feb; 2(2):e255. PubMed ID: 17327916
[TBL] [Abstract][Full Text] [Related]
11. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
[TBL] [Abstract][Full Text] [Related]
12. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
13. Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression.
Morales La Madrid A; Nall MB; Ouyang K; Minor A; Raca G; Kent P; Miller I; Schleiermacher G; Janoueix-Lerosey I; Cohn SL
Pediatr Blood Cancer; 2013 Feb; 60(2):332-5. PubMed ID: 22997192
[TBL] [Abstract][Full Text] [Related]
14. Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors.
Brunner C; Brunner-Herglotz B; Ziegler A; Frech C; Amann G; Ladenstein R; Ambros IM; Ambros PF
PLoS One; 2016; 11(8):e0161369. PubMed ID: 27560999
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
16. Why Is Aneuploidy Associated with Favorable Outcome in Neuroblastoma?
Tonini GP
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439783
[TBL] [Abstract][Full Text] [Related]
17. Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors.
Valent A; Guillaud-Bataille M; Farra C; Lozach F; Spengler B; Terrier-Lacombe MJ; Valteau-Couanet D; Danglot G; Lenoir GM; Brison O; Bénard J; Bernheim A
Cancer Genet Cytogenet; 2004 Aug; 153(1):10-5. PubMed ID: 15325088
[TBL] [Abstract][Full Text] [Related]
18. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
20. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
